financetom
Business
financetom
/
Business
/
Paytm denies reports of levying merchant fee on transactions
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Paytm denies reports of levying merchant fee on transactions
Jul 1, 2019 2:18 AM

Digital payments platform Paytm denied reports that the company will charge transaction fees to customers beginning July 1. The Economic Times today reported that Paytm will now pass on the merchant discount rate (MDR) to its customers, making transactions through Paytm costly.

The move would help reduce the burn rate of the SoftBank-backed company and turn it profitable, reported ET, citing two people aware of the development.

Paytm has clarified that the company does not charge any convenience fee from customers on using any payment method.

"There have been few merchants like educational institutes or utility service providers who do not absorb credit card charges and expect customers to pay the same. We would like to reiterate that these charges aren’t levied by Paytm in any scenario," said Paytm.

The payment firm also added that it does not plan to levy any such charges in future.

MDR is charged by banks and card companies to customers for digital transactions.

For Paytm, the charge amounts to 1 percent on payments through credit cards, 0.9 percent for debit cards and up to Rs 12-15 for transactions by net banking and the Unified Payments Interface (UPI), one of the sources told ET, adding that Paytm has been absorbing the charge and has not been charging anything extra for payments made through the platform.

First Published:Jul 1, 2019 11:18 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Albemarle Unusual Options Activity
Albemarle Unusual Options Activity
Mar 7, 2024
Investors with a lot of money to spend have taken a bullish stance on Albemarle . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALB,...
CompoSecure Shares Rise After Q4 Results Top Estimates
CompoSecure Shares Rise After Q4 Results Top Estimates
Mar 7, 2024
01:44 PM EST, 03/07/2024 (MT Newswires) -- CompoSecure ( CMPO ) shares jumped 30% in recent Thursday trading, a day after the company reported Q4 earnings and revenue that topped estimates by analysts. The company on Wednesday reported Q4 adjusted diluted earnings of $0.26 a share, up from $0.20 a year earlier. Analysts polled by Capital IQ expected $0.23. Revenue...
EV maker Rivian unveils smaller, less expensive SUVs, crossovers
EV maker Rivian unveils smaller, less expensive SUVs, crossovers
Mar 7, 2024
LAGUNA BEACH, California (Reuters) -Rivian on Thursday unveiled its smaller and less expensive R2 SUVs and R3 crossovers amid a slowdown in demand for EVs and also said it would start producing the R2 at its existing facility in Illinois to ensure deliveries in 2026. Rivian shares were up 10% at $12.16 on Thursday afternoon. The R2, with a starting...
Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday?
Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday?
Mar 7, 2024
Thursday, Alligator Bioscience AB and Aptevo Therapeutics Inc ( APVO ) released interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for solid tumors likely to express the tumor antigen 5T4. The multi-center, dose-escalation trial is now more than 50% enrolled, and preliminary results include: Treatment was overall well-tolerated, and a maximum tolerated dose has not yet been determined. Dose...
Copyright 2023-2025 - www.financetom.com All Rights Reserved